TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06221696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Fiber Supplement Group
Description: Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Three daily packets of placebo powder, taken 30 minutes before each main meal.
Study: NCT04702087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OLEP
Description: omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric formula
Study: NCT05729334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinicgram Euclides
Description: Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator.
Study: NCT05935579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib Oral Product
Description: The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
Study: NCT05552820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Electroacupuncture
Description: Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electroacupuncture
Description: Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
Study: NCT03856437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccination messages
Description: Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccination messages
Description: Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccination messages
Description: Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
Study: NCT06310512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured drug therapy management
Description: Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
Study: NCT05114304

Intervention type: OTHER
Intervention: Evaluation of co-morbid psychiatric disorders
Description: Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes
Study: NCT06290401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCThrive
Description: SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
Study: NCT06171126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Faeces
Description: Faeces from donor selected based on European guidelines, compared to own faeces (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Faeces
Description: Faeces from donor selected based on European guidelines, compared to own faeces (placebo)
Study: NCT06290401

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SCHealthED
Description: Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
Study: NCT04583813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin 10 mg oral tablet, once daily, for 24 months
Study: NCT06437015

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy
Description: patient's unaffected hand is tied with a triangular bandage or splint and the patient asks to perform the exercise through the affected hand. for up to 6 hours a day for 5days week /4 weeks and the patient nonparetic arm restrained from the use by having the patient placing a mitt on the hand or a sling on the unaffected hand, forcing the use of the affected limb to promote purposeful movements when performing functional tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: In this group training was given for 45min a day for 5 days a week for 4 weeks. Mirror box which was of 18×24inch \[was placed on the learning table and exercises were carried out by the patient looking into the mirror where an unaffected limb is placed in front of the mirror, through looking into the mirror patient assumes the reflection of the unaffected limb as the paretic limb. Exercises performed were hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation
Study: NCT06171126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Faeces
Description: Faeces from donor selected based on European guidelines, compared to own faeces (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Faeces
Description: Faeces from donor selected based on European guidelines, compared to own faeces (placebo)
Study: NCT06197100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care training
Description: The program includes breastfeeding teaching, baby massage, managing gas issues (shaking, white noise), and nutrition for mothers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control grups
Description: Mothers in this group will be given an educational brochure containing information about colic.
Study: NCT05850325

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1 Elbow Flexed at 90 Degrees
Description: subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Elbow Fully Flexed
Description: subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
Study: NCT05989464

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-swab for genital HPV
Description: Participants will insert a swab in the vagina to collect a sample for HPV testing.
Study: NCT04583813

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empagliflozin matching placebo, once daily, for 24 months
Study: NCT05737394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP Block
Description: Laparoscopically-assisted placement of block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided TAP Block
Description: Ultrasound-assisted placement of block
Study: NCT06425822

Intervention type: DIAGNOSTIC_TEST
Intervention: Left atrial electroanatomical mapping
Description: Left atrial electroanatomical mapping (substrate and functional mapping)
Study: NCT04937881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
Study: NCT04747470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion
Study: NCT06415227

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vericiguat
Description: The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
Study: NCT05701696

Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitization inventory
Description: Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.

Intervention type: DIAGNOSTIC_TEST
Intervention: Widespread pain index
Description: Total the number of painful body areas

Intervention type: DIAGNOSTIC_TEST
Intervention: Symptom severity scale
Description: The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms

Intervention type: OTHER
Intervention: Fibromyalgia impact questionnaire
Description: A tool to assess health status in fibromyalgia

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: An instrument for detecting depression and anxiety

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-Leeds Assessment of Neuropathic Symptoms and Signs
Description: An instrument used to identify pain of neuropathic origin
Study: NCT05483075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCP-Guided Exercise Training Program
Description: Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR).
Study: NCT05697900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Hydrochloride
Description: The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
Study: NCT05071092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Description: Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
Study: NCT04747470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion
Study: NCT05130411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DLM - Test product
Description: The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
Study: NCT05268861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error Augmentation Feedback
Description: Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Error Augmentation Feedback
Description: Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
Study: NCT04747470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered as an IV infusion
Study: NCT04763629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Patients of both arms will undergo two different modalities of exercise during the 12 weeks study period.
Study: NCT04907344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study: NCT06143176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based occupational therapy
Description: All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
Study: NCT06189482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
Study: NCT05708456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application with symptom management
Description: In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.